Navigation Links
Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
Date:1/28/2008

esearch and development expenses were $1.6 million for the fourth quarters of fiscal 2007 and 2006. For the fiscal year, research and development expenses were $7.0 million in fiscal 2007 compared to $6.7 million in 2006. For the fiscal year, the increase was primarily due to increases in employee-related expenses and spending on preclinical studies compared to fiscal 2006. These increases were partially offset by lower spending on outside services and on regulatory filing fees.

Sales and marketing expenses increased to $290,000 for the fourth quarter of fiscal 2007, from $147,000 for the same period in 2006, mainly due to increased spending for sales activities in South Africa. For the 2007 fiscal year, sales and marketing expense increased to $1.4 million compared to $671,000 in fiscal 2006, due to planning activities for Hemopure in the U.K. and increased spending in South Africa.

General and administrative expenses were $1.8 million for the fourth quarter of fiscal 2007 compared to $2.5 million for the corresponding period in 2006 due to lower consulting and legal expenses. For the 2007 fiscal year, general and administrative expenses were $8.2 million for fiscal 2007 compared to $9.3 in fiscal 2006 primarily due to lower consulting, legal and severance expenses and insurance premiums in 2007.

The company recorded a one-time, non-cash impairment charge of $11.3 million in the fourth quarter of fiscal 2007 for an asset consisting of engineering and design of a large-scale manufacturing facility. The adjustment was recorded during the audit of the 2007 financial statements. The company determined this asset was impaired pursuant to the applicable accounting rules, primarily due to continued delays in plans to construct the facility, significant clinical and US regulatory delays and a modification in clinical development strategy. However, if Hemopure is approved for an indication with broad application in a major market, the company believes t
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... WEDNESDAY, Dec. 1 (HealthDay News) -- The case of a ... -- and actually got better -- sheds light on how ... suggests. "Our findings in this case report suggest that ... roundworm can alleviate the symptoms of ulcerative colitis," said study ...
... , This release is available in French ... and the brain appear to be even more closely connected ... apparently not confined to the heart, but also affect the ... the level of the brainstem, which leads to insomnia, notably ...
... -- A "virtual biopsy" may help diagnose a degenerative ... others who suffer repeated blows to the head, says ... encephalopathy (CTE) can include memory problems, impulsive and erratic ... marked by an accumulation of abnormal proteins in the ...
... Alex Mitchell, of the Department of Cancer Studies and ... study which has been published in the journal ... screening refers to population based medical tests such as ... detect conditions such as cancer, diabetes or heart ...
... Dec. 1 (HealthDay News) -- A test that measures the ... at an early stage and help doctors evaluate the effectiveness ... as early as possible -- before it destroys the optic ... the researchers, from the Bascom Palmer Eye Institute at the ...
... HealthDay Reporter , TUESDAY, Nov. 30 (HealthDay News) ... directions on the labels of over-the-counter kids, medicines may ... that most of the popular cough-and-cold, pain-relieving, allergy and ... begin with. Nor is there much consistency in product ...
Cached Medicine News:Health News:Worm Therapy Shows Promise for Ulcerative Colitis 2Health News:Worm Therapy Shows Promise for Ulcerative Colitis 3Health News:Insomnia after myocardial infarction 2Health News:Imaging May Reveal Sports-Related Brain Disorder at Early Stage 2Health News:People with mental illness receive inadequate mass screening for prevention of medical conditions 2Health News:Confusing Labeling Found on Many Nonprescription Kids' Meds 2Health News:Confusing Labeling Found on Many Nonprescription Kids' Meds 3
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
(Date:10/20/2014)... 20, 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Surgeons Annual Meeting that they have joined forces ... The collaboration is the first of its kind ... patient outcomes. NICO,s BrainPath® interventional access technology and ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... Mass. , May 5 LightLab Imaging, ... Optical Coherence Tomography (OCT) technology for vascular and other ... and Drug Administration (FDA) for the C7-XR Imaging System ... LightLab,s latest generation Frequency Domain OCT (FD-OCT™) technology, are ...
... May 5 Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH) ... Care Conference in New York, New York , on May 11, 2010 , ... , , A live ... .  The webcast will be archived for replay following the conference. , ...
Cached Medicine Technology:LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 2LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 3LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 4Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference 2
... IMMULITE and IMMULITE 1000 ... with the IMMULITE and IMMULITE ... analyzers which offer simplicity in ... systems can be found in ...
... Anti-Nuclear Antibodies (ANAs) has long been an ... rheumatic diseases. The antigens used in their ... of human or animal nuclei, this has ... Antigens (ENAs). The most commonly measured ENA ...
... Automation, Inc. (DAI) ENA Profile Enzyme-Linked Immunosorbent ... of antibodies in human serum to individually ... Scl-70 and Jo-1 in a single serum ... to be used as an aid in ...
... Enzyme-linked immunosorbent assays for the ... antibodies to extractable nuclear antigens ... Antibodies to Sm aid in ... erythematosus (SLE). ,RNP antibodies aid ...
Medicine Products: